Research programme: pegylated relaxin - Bristol-Myers Squibb/Ambrx

Drug Profile

Research programme: pegylated relaxin - Bristol-Myers Squibb/Ambrx

Alternative Names: ARX-720; PEG-relaxin

Latest Information Update: 18 Jan 2013

Price : $50

At a glance

  • Originator Ambrx
  • Developer Ambrx; Bristol-Myers Squibb
  • Class Peptide hormones
  • Mechanism of Action Peptide hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 31 Dec 2012 Preclinical development is ongoing in USA
  • 22 Sep 2011 Preclinical trials in Heart failure in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top